Novo Nordisk ($NVO) has been some of the influential healthcare corporations due to its weight problems medication Ozempic and Wegovy. These merchandise modified the burden loss trade, drove explosive income development and briefly made Novo Nordisk Europe’s most respected firm. However 2025 has marked a pointy reversal. The inventory is down about 50 % for the 12 months, signalling a serious shift in investor expectations. The query is easy: is that this the start of a protracted decline, or the sort of reset that creates alternative for long-term buyers?
1. The Twist in Novo’s Journey
The turning level started in the US, which accounts for 58 % of Novo Nordisk’s income. Development expectations have been minimize a number of occasions, Wegovy demand softened, and round a million People shifted to cheaper compounded semaglutide, pulling significant quantity away. On the identical time, Eli Lilly expanded provide of Mounjaro and Zepbound and secured broader insurance coverage protection, rising aggressive stress.
Pipeline updates added to the weak point. CagriSema delivered 22.7 % weight reduction, robust however beneath investor expectations, and the inventory dropped about 10 %. Just lately, an Alzheimer’s trial failed, pushing shares to a four-year low and elevating questions on Novo’s pipeline outdoors GLP-1 medicines.
A management transition created additional uncertainty. New CEO Mike Doustdar tried a ten billion greenback takeover of Metsera, however Pfizer received the bid with a decrease supply and regulators flagged consolidation issues. The scenario break up buyers between seeing strategic imaginative and prescient and seeing urgency.
2. Resetting the Playbook
Dealing with stress on development, pricing and provide, Novo Nordisk launched a broad strategic reset. The corporate minimize out-of-pocket costs for Ozempic and Wegovy to 199 {dollars} for starter doses and 349 {dollars} month-to-month, with Medicare pricing set to drop towards 245 {dollars} and oral GLP-1 choices possible close to 149 {dollars} by 2027. The aim is to broaden entry and gradual the migration towards compounded options.
On the identical time, Novo is investing greater than 9 billion {dollars} in 2025 to broaden international manufacturing. This consists of doubling U.S. manufacturing together with main expansions in Denmark, France, China and Brazil. Some provide tightness is anticipated by 2025 as amenities ramp up.
To help this shift, Novo Nordisk can also be restructuring. About 9,000 jobs (roughly 11 % of the workforce) will likely be eradicated, together with 5,000 roles in Denmark. Hiring continues in manufacturing, medical growth and business areas, whereas nonessential recruitment is frozen.
3. What the Numbers Reveal
Regardless of the challenges, Novo Nordisk continues to ship robust monetary efficiency. Within the first 9 months of 2025, gross sales reached DKK 229.9 billion, up 12% 12 months over 12 months, whereas working revenue grew 5% to DKK 95.9 billion. Weight problems care remained the strongest engine, with gross sales rising 41% at fixed alternate charges to DKK 59.9 billion. EBITDA reached DKK 112.3 billion, reflecting one of many highest profitability ranges within the international pharmaceutical trade.
What stands out most is the valuation reset. Novo Nordisk now trades at:
P/E round 13• ahead P/E round 12• EV/EBITDA round 9• value to gross sales round 4.3• value to e book round 8
Traditionally Novo Nordisk traded at a P/E between 22 and 27. The present valuation is due to this fact 40–50% beneath its long run common.
The market not costs Novo Nordisk as a high-growth innovator and is now valuing it extra like a mature pharmaceutical firm. This shift cuts each methods. If development weakens once more, the inventory may fall additional, however the decrease valuation additionally provides Novo room to outperform if situations begin to stabilize.
To shift sentiment the corporate might want to ship on three areas:
stabilisation of Wegovy demand• profitable growth into excessive quantity applications comparable to Medicare, TrumpRx and decrease priced tiers• a aggressive pipeline, particularly the oral weight problems drug anticipated in 2026 and future CagriSema growth
If these parts strengthen, right now’s valuation might show overly pessimistic.
4. Will the Inventory Recuperate or Fall Additional?
The long run course of the share value will rely on a number of components, however the scenario is now extra outlined than earlier within the 12 months. The primary challenges, weaker US demand, stronger competitors and a narrowed full 12 months outlook are already recognized and mirrored within the share value. The main focus now shifts to how Novo Nordisk manages the subsequent stage.
What’s going to buyers look within the close to future:• updates on Wegovy demand in the US• the size of compounded GLP 1 use• any changes to 2025 steerage
These areas nonetheless affect how rapidly efficiency within the US market can stabilize.
Wanting additional forward, a number of milestones may form the medium time period outlook, though most of them fall in 2026 or later:
the launch of the oral weight problems drug• regulatory choices that have an effect on pricing or entry• growth into massive quantity applications comparable to Medicare• new medical information from pipeline candidates
Novo Nordisk ($NVO) stays a major international participant with robust monetary efficiency, however the atmosphere round it has turn out to be extra complicated. Competitors, pricing stress and regulatory components are more likely to proceed affecting the inventory as new info emerges. The general course is open, and the subsequent section will rely on firm execution and broader market situations.
This communication is for info and schooling functions solely and shouldn’t be taken as funding recommendation, a private advice, or a suggestion of, or solicitation to purchase or promote, any monetary devices. This materials has been ready with out considering any explicit recipient’s funding goals or monetary scenario and has not been ready in accordance with the authorized and regulatory necessities to advertise unbiased analysis. Any references to previous or future efficiency of a monetary instrument, index or a packaged funding product will not be, and shouldn’t be taken as, a dependable indicator of future outcomes. eToro makes no illustration and assumes no legal responsibility as to the accuracy or completeness of the content material of this publication.
_id_4ad88908-5240-4cf5-8c53-628cb3152b9f_size900.jpg)
